Until recently, biosimilars industry analysts had predicted that Johnson & Johnson’s immunology blockbuster Stelara (ustekinumab) could face US competition before the end of 2023, with the September expiry of a key patent protecting the top-selling brand.
However, recent developments have now upset those expectations, with a pair of separate settlements over ustekinumab biosimilars suggesting that the industry could be in for a rerun of the Humira (adalimumab) saga that saw multiple competitors individually all settle with originator AbbVie, setting up
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?